Drug Loss in Japan: A Comparative Analysis with Europe for New Drugs Developed by Emerging Biopharma Companies

Documenti analoghi

• Background Factors Contributing to Safety Warning Discordance in the Initial Labeling of New Drugs in Japan, the United States, and the European Union
  di: Koichi Fukuda, et al.
  Pubblicazione: (2024)
• Emerging Tools and Technologies for Microbiome‐Aware Drug Development
  di: Henry J. Haiser, et al.
  Pubblicazione: (2025)
• New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
  di: Amitava Mitra, et al.
  Pubblicazione: (2024)
• Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
  di: Vaishali Sahasrabudhe, et al.
  Pubblicazione: (2025)
• A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
  di: Simeon Rüdesheim, et al.
  Pubblicazione: (2025)